Concerning – The FDA Is Approving Drugs After Fewer Trials and Providing Less Information to the Public

FDA approves the first treatment for nasopharyngeal carcinoma, a rare cancer that originates in the nasopharynx. The drug (toripalimab-tpzi) is a next-generation, programmed death receptor-1 monoclonal antibody. Because of the tumor's location (behind the nose), surgery is not usually an option.

FDA Issues Eye Drops Warning After Deadly Outbreak of Bacterial Infections

Public Invited to International Observe the Moon Night Oct. 21